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The nasal cavity and turbinates play important physiological functions by filtering, warming 
and humidifying inhaled air. Paranasal sinuses continually produce nitric oxide (NO), a 
reactive oxygen species that diffuses to the bronchi and lungs to produce bronchodilatory 
and vasodilatory effects. Studies indicate that NO may also help to reduce respiratory tract 
infection by inactivating viruses and inhibiting their replication in epithelial cells cultured in 
vitro. In view of the pandemic caused by the novel coronavirus (SARS-CoV-2), clinical 
trials have been designed to examine the effects of inhaled nitric oxide in COVID-19 
subjects. We discuss here additional lifestyle factors such as mouth breathing which may 
affect the antiviral response against SARS-CoV-2 by bypassing the filtering effect of the 
nose and by decreasing NO levels in the airways. Simple devices that promote nasal 
breathing during sleep may help prevent the common cold, suggesting potential benefits 
against coronavirus infection. In the absence of effective treatments against COVID-19, the 
alternative strategies proposed here should be considered and studied in more detail. 
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The first cases of COVID-19 pneumonia caused by the novel coronavirus 
(SARS-CoV-2) were reported in Wuhan, China, in December 2019 [1,2]. Within a few 
months, SARS-CoV-2 had spread to most countries around the globe and is now responsible 
for more than 3,400,000 infections and 240,000 deaths, leading the World Health 
Organization to declare a worldwide pandemic crisis in March 2020. While early travel 
restrictions, quarantine measures, and face masks have helped to reduce the spread of the 
virus [3], new means to prevent and treat COVID-19 infections are urgently needed. 
Inhalation of nitric oxide (NO) gas is currently being investigated as a preventive 
measure and treatment against COVID-19 (e.g., clinical trials NCT04306393, 
NCT04312243, NCT04338828, NCT04305457). Inhaled NO therapy has been used as 
rescue treatment to improve arterial oxygenation against acute respiratory distress syndrome 
(ARDS) [4], which represents a major complication of COVID-19. During the 2002–2003 
severe acute respiratory syndrome (SARS) epidemic, also caused by a coronavirus, inhaled 
NO was tested in six SARS patients, producing beneficial effects that include decreased 
pulmonary hypertension, improved arterial oxygenation, and reduced spread and density of 
lung infiltrates [5]. Surprisingly, humming increases nasal NO by 15 times in the airways 
[6]. Other possible options to increase NO levels in the human body include NO donor 
molecules (e.g., arginine, citrulline, nitroglycerin), phosphodiesterase inhibitors (e.g., 
Viagra) and nitrate-rich foods such as leafy green vegetables, beetroots and herbal spices 
[7,8], although the effects may be less targeted to the respiratory tract in these cases.  
The rationale for using inhaled NO against SARS-CoV-2 infection stems from the fact 
that this molecule plays a major role in pulmonary and cardiovascular physiology. NO is a 
reactive oxygen species (ROS) that is continually produced by epithelial cells of the 
paranasal sinuses and nasopharynx via NO synthase (NOS) enzymes [9]. Produced at 10 
parts per million (ppm) in the human sinuses, NO can diffuse to the bronchi and lungs, 
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where it induces vasodilatory and bronchodilatory effects [9-11]. NO also activates ciliary 
movement [12] and mucus secretion [13], which can increase removal of dust and viral 
particles from the respiratory tract. Notably, NO produces antimicrobial effects against a 
broad range of microbes including bacteria, fungi, helminths, protozoa and viruses, which 
may help prevent pulmonary infections [14,15]. NO inactivates viruses by modifying 
proteins and nucleic acids that are essential for viral replication [15], and can reduce 
replication of viruses in vitro, including herpesvirus [16], rhinovirus [17], hantavirus [18], 
Coxsackie virus [19], Japanese encephalitis virus [20], retrovirus [21], vaccinia virus [22], 
and the SARS coronavirus [23-25]. NO also inhibits pulmonary viral replication in an 
experimental animal model in pigs [26]. In humans, higher basal levels of exhaled NO are 
associated with fewer symptoms of the common cold [27], suggesting that nasally-produced 
NO represents one of the body’s endogenous defense mechanisms against viruses in the 
airways.  
Nonetheless, a study showed that inhaled NO at 80 or 160 ppm failed to improve 
survival or viral load in mice infected intranasally with a lethal dose of influenza virus [28]. 
Moreover, high levels of NO are produced by epithelial cells and leukocytes in subjects 
with acute viral infection and asthma, as seen by increased orally-exhaled NO levels under 
these conditions [29,30]. High exhaled NO levels are currently used as a marker for 
eosinophilic airway inflammation in asthmatic subjects [31], and some authors propose that 
NO may contribute to tissue damage during airway inflammation [15,32]. It thus remains to 
be seen whether increasing NO levels by inhalation or treatment with NO donors may 
produce antiviral effects in COVID-19 subjects. The possible effect of inhaled NO on 
bronchodilation and oxygenation appears promising, especially in view of the current 
shortage of ventilators. 
Conversely, low NO levels in the airways may facilitate SARS-CoV-2 infection and 
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the development of COVID-19 in some individuals. Accordingly, conditions associated with 
reduced nasal NO production, including Kartagener’s syndrome [33] and cystic fibrosis [34], 
are associated with recurrent respiratory infections and inflammation. Similarly, mice that 
are deficient in NOS or that are treated with NOS inhibitors are also susceptible to viral 
infections [35,36]. In the general population, orally-exhaled and nasal NO levels are 
reduced in white people (compared to Asians) and in individuals who smoke or consume 
alcohol, caffeine, or corticosteroids [37-39] (Figure 1).  
Another phenomenon that reduces NO levels in the airways—as well as the filtering, 
warming and humidifying effects of the nose on inhaled air—is mouth breathing. 
Measurements indicate that mouth breathers have lower levels of NO within the respiratory 
tract compared to nasal breathers [40]. Mouth breathing has been associated with many 
health issues, including abnormal facial and dental development, cardiovascular disease, 
fatigue, halitosis, headaches, hypertension, inflammation, sleep apnea, snoring, stress, and 
tooth decay, to name a few [41-44]. While most people spontaneously report breathing 
through the nose, mouth breathing may occur during talking, exercise and sleep or in people 
with allergies, congestion or nasal obstruction, suggesting that it may be more prevalent 
than usually appreciated. For instance, switching between nasal and mouth breathing is 
common during sleep, especially in older individuals [45]. Studies indicate that individuals 
who snore or breathe through the mouth during sleep—conditions which are highly 
prevalent in males—are more likely to develop respiratory tract infections [46]. Our 
anecdotal observations also suggest that favoring nasal breathing during sleep by sealing the 
mouth with adhesive tape reduces common colds. This phenomenon may be due to the 
filtration and humidifying effects of the nose on inhaled air and to increased NO levels in 
the airways, which may decrease viral load during sleep and allow the immune system more 
time to mount an effective antiviral response. Conversely, following viral infection of 
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airway epithelial cells, constant or intermittent mouth breathing in daytime and during sleep 
may reduce the beneficial effects of the nose and NO against the virus, therefore leading to 
unobstructed viral replication (Figure 1). Mouth breathing during sleep may therefore 
worsen the symptoms of COVID-19, consistent with the observation that symptoms of 
respiratory infections are usually worse in the morning. 
The studies described here suggest that therapies designed to increase airway NO 
levels via gas inhalation and donor molecules may improve oxygenation and produce health 
benefits in COVID-19 subjects. In addition, limiting the lifestyle factors that reduce 
endogenous NO levels in the airways—such as mouth breathing and smoking—may also 
help to reduce SARS-CoV-2 viral load and symptoms of COVID-19 pneumonia by 
promoting more efficient antiviral defense mechanisms in the respiratory tract. In the 
absence of effective treatments targeting SARS-CoV-2, we believe that these strategies 
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Fig. 1. Potential effects of nasal breathing and nitric oxide on SARS-CoV-2 viral load and 
oxygenation. Nasal breathing may reduce viral load and improve oxygenation in COVID-19 
subjects by filtering the air and by increasing NO levels in the airways. Several factors may 
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